Interview with Jose Manuel Lezama , General Manager, BSN Medical Mexico
When you joined BSN Medical 3 years ago, what was the roadmap set in place for the growth and development of the company? Which opportunities did the company see in…
Address: Asturias 39. Col. Insurgentes Mixcoac Delegacion Benito Juarez C.P. 03920 México City,Mexico
Tel: 52,55,5482,5400
Web: http://mexico.bsnmedical.com/
BSN medical was established in April 2001 as a 50:50 joint venture between Beiersdorf AG, Hamburg, and Smith & Nephew plc, London due to complementary geographic and channel strengths in the areas of wound care, fracture management, physiotherapy and compression therapy. BSN medical was acquired in 2006 by Montagu Private Equity, a leading private equity investor in the European mid-market, with a large pool of available funds, with values ranging from € 100 million to € 1+ billion. Since then, BSN was developed as a fully independent global player in the health care market. Under Montagu’s ownership BSN medical successfully completed 4 acquisitions, further developed the global independency and continued the portfolio upgrade through highly innovative product launches (e.g. Advanced Wound Care).
BSN medical focuses on developing world-class products that offer high quality solutions for both caregivers and patients.
We are one of the world’s leading suppliers in the medical product segments of casting, bandaging, traditional wound care and compression therapy.
When you joined BSN Medical 3 years ago, what was the roadmap set in place for the growth and development of the company? Which opportunities did the company see in…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract…
Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent…
In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms…
Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an…
This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth.…
Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical…
Enrique Giraud de Haro, President & GM at Fujifilm Mexico, highlights the company’s growth alongside Fujifilm’s expansion in the region. He discusses the importance of fostering a preventive healthcare culture,…
Some 16 percent of Mexico’s population is battling diabetes—a number that represents one in five of the nation’s populace without including the vast numbers of undiagnosed Mexicans living with the…
See our Cookie Privacy Policy Here
